Novel Engineering & Consulting, LLC

Empowering Life Science Innovators Through Design and Engineering

Website

About the firm

Novel Engineering & Consulting, LLC is a life science architecture, engineering, and consulting firm based in Kansas City, Kansas. It specializes in pharmaceutical, biopharmaceutical, novel therapies, medical device, and animal health manufacturing facilities, bringing owner-side operational experience together with technical design expertise to guide clients from front-end planning through construction closeout. Its integrated approach combines process, MEP, and architecture disciplines to optimize facility performance and support regulatory compliance.

Firm type
Architecture & Engineering · Process Engineering

Capabilities

Technical Consulting

Service website

Expert guidance on pharmaceutical and life science facility challenges, drawing on owner-side operational experience.

Compliance Assessment

Service website

Regulatory and compliance evaluations for pharmaceutical manufacturing facilities against FDA and international standards.

Early Project Planning

Service website

Feasibility and front-end engineering studies that define scope, cost, and schedule before detailed design begins.

Project Management & Execution

Service website

End-to-end project management and controls from conceptual planning through construction closeout.

  • Project Controls

Design & Engineering

Service website

Integrated architecture and engineering design for life science manufacturing facilities.

  • Process Architecture
  • Process Engineering
  • MEP Engineering
  • Detailed Design

Construction & Post-Construction Support

Service website

Construction administration and post-construction commissioning support for pharmaceutical and life science facilities.

Master Planning

Service website

Strategic facility master planning aligned with long-term production and regulatory objectives.

Industries

Pharmaceutical · Life Sciences · Laboratories · Medical Devices

Projects

No projects listed yet.